Signals from SABR-COMET time to move on to phase III studies
- PMID: 32016034
- PMCID: PMC6976417
- DOI: 10.21037/atm.2019.09.152
Signals from SABR-COMET time to move on to phase III studies
Conflict of interest statement
Conflicts of Interest: The authors have no conflicts of interest to declare.
Comment on
-
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.Lancet. 2019 May 18;393(10185):2051-2058. doi: 10.1016/S0140-6736(18)32487-5. Epub 2019 Apr 11. Lancet. 2019. PMID: 30982687 Clinical Trial.
References
-
- Weichselbaum RR. The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis-From Conception to Treatment. J Clin Oncol 2018:JCO1800847. - PubMed
-
- Rubin P, Green J. Solitary Metastases. Springfield, IL: C. C. Thomas 1968.
-
- Rosenberg SA. Surgical treatment of metastatic cancer. Philadelphia, PA: Lippincott Williams & Wilkins, 1987.
Publication types
LinkOut - more resources
Full Text Sources